Professional Documents
Culture Documents
Shorea Hemsleyana Stilbenoids Isolated From Stem Bark of PDF
Shorea Hemsleyana Stilbenoids Isolated From Stem Bark of PDF
1001
lation of 3 yielded a pentamethyl ether (3a) which further afforded a monoacetate (3b), suggesting that 3 has one alcoholic hydroxyl and five phenolic groups. Thus, the remaining
oxygen was attributed to an ether linkage in 3. The 1H-NMR
spectrum (Table 1) showed the presence of two sets of orthocoupled aromatic protons assignable to two 4-hydroxyphenyl
groups [d 7.48 (2H, d, J58.3 Hz, H-2a, 6a) and 6.94 (2H, d,
J58.3 Hz, H-3a, 5a); d 6.72 (2H, d, J58.3 Hz, H-2b, 6b) and
6.48 (2H, d, J58.3 Hz, H-3b, 5b), two sets of meta-coupled
aromatic protons on a 1,2,3,5-tetrasubstituted benzene ring [d
6.24 (1H, br s, H-12a) and 6.23 (1H, br s, H-14a); d 6.04
(1H, d, J52.0 Hz, H-12b) and 5.70 (1H, d, J52.0 Hz, H14b)], an alcoholic hydroxyl group [d 4.45 (br s)] and five
phenolic hydroxyl groups [d 8.63, 7.91 (32), 8.01 and 8.02]
in addition to two sets of mutually coupled aliphatic protons
[d 5.75 (1H, d, J59.8 Hz, H-7a), 5.41 (1H, d, J59.8 Hz, H8a); d 5.07 (1H, d, J55.9 Hz, H-7b), 4.76 (1H, br d, H-8b)].
The CH-COSY spectrum gave the complete assignment of
all protonated carbons as shown in Table 2. In the HH longrange COSY spectrum, the oxymethine proton (H-7a) had a
correlation with H-2a (6a) on ring A1, and H-8a had a correlation with H-14a on ring A2. In the COLOC spectrum (Fig.
3), significant correlations were observed between C-2a(6a)/
H-7a, C-8a/H-14a, C-9a/H-7a, C-10b/H-8a, C-10b/H-12b
and C-11b/H-8a, respectively. These results indicated that
one set of benzylic methine protons (H-7a and H-8a) was assigned to the protons on a dihydrofuran ring. On the other
hand, the HH long-range COSY spectrum showed that the
aliphatic hydroxyl proton at d 4.45 was coupled with H-8b,
the signal of which underwent a low-field shift in the 1HNMR spectrum of 3b and a hexa-acetate (3c), indicating the
presence of a secondary alcohol substituent at C-8b. In the
COLOC spectrum, long-range correlations were observed
between C-11a/H-7b, C-10b/H-8b C-2b(6b)/H-7b and C-9b/
OH-8b. From the above results, the planar structure of 3
could be depicted as in Fig. 3. The relative stereochemistry
was substantiated by means of NOE spectrum (Fig. 4). NOEs
between H-7a/H-14a, H-8a/H-2a(6a) and H-8b/H-2b(6b) in 3
indicated that both methine protons on the dihydrofuran ring
(7a and 8a) and the remaining two methine protons (7b and
8b) were trans. NOEs were also observed between H-8a and
the protons attributed to the acetyl group in 3b. Consequently, the relative stereochemistry of 3 was confirmed as
shown in Fig. 4. Previously, two resveratrol dimers having a
2000 Pharmaceutical Society of Japan
1002
Fig. 1
ortho-coupled aromatic protons assignable to three 4-hydroxyphenyl groups [d 7.08 (2H, d, J58.5 Hz, H-2a, 6a) and 6.75
(2H, d, J58.5 Hz, H-3a, 5a); d 7.16 (2H, d, J58.8 Hz, H-2b,
6b) and 6.59 (2H, d, J58.8 Hz, H-3b, 5b); d 7.29 (2H, d, J5
8.8 Hz, H-2c, 6c) and 6.88 (2H, d, J58.8 Hz, H-3c, 5c)], a
3,5-dihydroxyphenyl group [d 6.10 (2H, d, J52.0 Hz, H-10c,
14c) and 6.18 (1H, t, J52.0 Hz, H-12c)], a set of meta-coupled aromatic protons on a 1,2,3,5-tetrasubstituted benzene
ring [d 6.35 (1H, d, J52.0 Hz, H-12a) and 6.25 (1H, br s, H14a)], an aromatic proton on a penta-substituted benzene ring
July 2000
Table 1.
1003
1
No.
2a, 6a
3a, 5a
7a
8a
10a
12a
14a
2b, 6b
3b, 5b
7b
8b
10b
12b
14b
2c, 6c
3c, 5c
7c
8c
10c
12c
14c
OH
Glucose
6.24 (br s)
6.23 (br s)
6.72 (d, 8.3)
6.48 (d, 8.3)
5.07 (d, 5.9)
4.76 (br d)
6.26 (s)
No.
2, 6
3, 5
7
8
10
14
6.55 (s)
Glucose
Measured in acetone-d6 (400 MHz). All protons were assigned by 1H1H, 1H1H long-range, 13C1H COSY and COLOC spectrum.
1004
Table 2.
No.
No.
1a
2a, 6a
3a, 5a
4a
7a
8a
9a
10a
11a
12a
13a
14a
1b
2b, 6b
3b, 5b
4b
7b
8b
9b
10b
11b
12b
13b
14b
1c
2c, 6c
3c, 5c
4c
7c
8c
9c
10c
11c
12c
13c
14c
Glucose
131.5
127.4
111.5
157.3a)
85.9
45.9
139.2
120.4
158.80
96.0
158.9
105.7
132.0b)
127.7
115.5f)
157.7a)
89.5
52.3
138.2
119.2
161.2
96.4
160.3
105.3
131.8b)
128.1
115.5f)
157.8a)
95.1
55.2
140.7
118.3
161.1
97.5
160.2
108.0
132.2
128.0
116.0
158.0c)
86.6
47.0
139.9
121.0
160.9
96.8
159.6
106.4
132.4
128.5
116.2g)
158.4c)
90.0
53.0
138.8
122.5
161.6
98.3
161.3
106.8
132.3
128.9
116.2g)
158.6c)
95.8
55.8
141.0
118.9
161.9
98.3
159.5
108.9
101.9 (C-1)
74.8 (C-2)
71.5 (C-3)
77.8 (C-4)
78.0 (C-5)
62.8 (C-6)
133.8
130.4
116.4
155.6
93.3
51.9
141.4
118.4
158.3
102.0
156.6
106.6
135.2
130.5
114.9
158.5
49.3
78.4
140.9
118.1
160.7
96.2
158.5
108.2
130.9
129.9d)
115.9
158.4e)
88.1
50.1
142.5
120.7
156.6
101.3
157.2
105.1
133.0
129.8d)
114.9
158.1
45.4
70.7
137.7
119.5
159.7
91.4
161.9
121.2
134.4
128.1
116.1
155.8e)
93.8
58.1
147.5
106.8
159.4
101.7
159.4
106.8
1
2, 6
3, 5
4
7
8
9
10
11
12
13
14
Glucose
5
130.0
128.9
116.5
158.3
126.5
129.4
140.0
107.3
157.6
112.0
157.6
107.3
77.3 (C-1)
75.1 (C-2)
79.6 (C-3)
70.7 (C-4)
82.2 (C-5)
61.8 (C-6)
Fig. 3.
Fig. 4.
Fig. 5.
Fig. 6.
Fig. 2.
Experimental
1
H- and 13C-NMR spectra were recorded on a JNM EX-400 (JEOL) spectrometer. Chemical shifts are shown as d -values with tetramethylsilane
(TMS) as the internal reference. Peak multiplicities are quoted in Hz. Negative ion FAB-MS was measured on a JMS-DX-300 spectrometer equipped
with a JMA 3500 data analysis system (JEOL). UV spectra were recorded
July 2000
(114 mg) was obtained in pure form after recrystallization (CHCl3acetone)
from fr. 22 [CHCl3MeOH (10 : 1) fraction]. Fr. 23 [CHCl3MeOH (10 : 1)
fraction] was further chromatographed by vacuum liquid chromatography
(VLC) using CHCl3MeOH mixtures. The CHCl3MeOH (10 : 1) fraction
afforded 3 (30 mg) after purification on a Sephadex LH 20 column (MeOH).
Fr. 25 [CHCl3MeOH (8 : 1)] was chromatographed repeatedly with VLC
(CHCl3MeOH and benzeneEtOAcMeOH system), Sephadex LH-20 column chromatography (MeOH), and preparative TLC (EtOAcCHCl3
MeOHH2O515 : 8 : 4 : 1) to afford 5 (5 mg) and 6 (15 mg). Compounds 2
(12 mg), 4 (12 mg), 7 (8 mg) and 8 (12 mg) were obtained from fr. 26
[CHCl3MeOH (8 : 1)] after purification by VLC (EtOAcCHCl3MeOH
H2O540 : 20 : 3 : 1) and preparative TLC (EtOAcCHCl3MeOHH2O5
15 : 8 : 4 : 1).
Compound 2 [(1)-a -Viniferin-13b-O-b -glucopyranoside] A pale yellow amorphous solid. Negative ion HR-FAB-MS: ([M2H]2) m/z 839.2327
(Calcd: for C48H39O14 839.2339); Negative ion FAB-MS: m/z 839 ([M2
H]2), 677 (M2H2glucopyranosyl moiety). UV l max (MeOH) nm: 228, 285.
1
13
[a ] 24
D 132 (c50.1, MeOH). The H- and C-NMR spectral data are listed
in Tables 1 and 2.
Acid hydrolysis of 2 Compound 2 (2 mg) was refluxed for 6 h with 3%
H2SO4 in MeOH. The reaction mixture was extracted with EtOAc and the
resulting solid was purified with PTLC [n-hexaneEtOAc (1 : 1)] to afford 1
(1 mg).
Compound 3 (Hemsleyanol A) A yellow amorphous solid. Negative
ion HR-FAB-MS ([M2H]2) m/z 469.1277 (Calcd for C28H21O7: 469.1287);
Negative ion FAB-MS: m/z 469 ([M2H]2). UV l max (MeOH) nm: 229, 285.
1
13
[a ] 24
D 214 (c50.1, MeOH). The H- and C-NMR spectral data are listed
in Tables 1 and 2.
Methylation of 3 Compound 3 (5 mg) was allowed to react with K2CO3
(2 g) and MeI (0.5 g) in dry acetone under reflux for 4 h. The reaction mixture was treated in the usual manner and the crude product (5 mg) was purified by PTLC [n-hexaneEtOAc (1 : 1)] to afford 3a as an amorphous colorless solid (4 mg). 1H-NMR (400 MHz, CDCl3) d : 3.50, 3.58, 3.60, 3.69, 3.86
(3H each, s, OMe35), 4.86 (1H, br s, H-8b), 5.20 (1H, br d, H-7b), 5.48
(1H, d, J510.3 Hz, H-8a), 5.77 (1H, d, J510.3 Hz, H-7a), 5.82 (1H, br s, H14b), 6.23* (1H, br s, H-14a), 6.24* (1H, d, J52.0 Hz, H-12a), 6.30* (1H, d,
J52.0 Hz, H-12b), 6.58 (2H, d, J58.8 Hz, H 3b, 5b), 6.77 (2H, d, J58.8 Hz,
H-2b, 6b), 7.03 (2H, d, J58.8 Hz, H-3b, 5a), 7.62 (2H, d, J58.8 Hz, H-2a,
6a) (* interchangeable).
Acetylation of 3b Compound 3a (4 mg) was dissolved in a mixture of
pyridine (1 ml), acetic anhydride (1 ml). The reaction mixture was kept at
room temperature for 24 h. The solution was treated in the usual manner and
the resulting crude product (4 mg) was purified by PTLC [n-hexaneacetone
(3 : 2)] to afford 3b as an amorphous colorless solid (2 mg). 1H-NMR
(400 MHz, CDCl3) d : 1.97 (3H, s, OAc), 3.55, 3.56, 3.59, 3.69, 3.87 (3H
each, s, OMe35), 5.21 (1H, d, J55.9 Hz, H-8b), 5.39 (1H, d, J510.2 Hz, H8a), 5.80 (1H, d, J510.2 Hz, H-7a), 5.87 (1H, d, J55.9 Hz, H-7b), 5.91 (1H,
br s, H-14b), 6.25* (2H, br s, H-12b, 14a), 6.28* (1H, br s, H-12a), 6.58 (2H,
d, J58.8 Hz, H-3b, 5b), 6.80 (2H, d, J58.8 Hz, H-2b, 6b), 7.04 (2H, d,
1005
J58.8 Hz, H-3b, 5a), 7.61 (2H, d, J58.8 Hz, H-2a, 6a) (* interchangeable).
Acetylation of 3 To a solution of 3 (2 mg) in pyridine (1 ml), acetic anhydride (1 ml) was added and the mixture was kept at room temperature for
24 h. The resulting crude product (2 mg) was purified by PTLC [n-hexane
EtOAc (3 : 2)] to afford 3c as an amorphous colorless solid (2 mg). 1H-NMR
(400 MHz, CDCl3) d : 2.00, 2.16, 2.17, 2.23, 2.24, 2.34 (3H each, s, OAc3
6), 5.09 (1H, d, J55.4 Hz, H-8b), 5.47 (1H, d, J59.3 Hz, H-8a), 5.92 (1H, d,
J55.4 Hz, H-7b), 5.92 (1H, d, J59.3 Hz, H-7a), 6.05 (1H, br s, H-14b), 6.49
(1H, d, J52.0 Hz, H-12b), 6.80 (1H, d, J52.0 Hz, H-12a)*, 6.84 (2H, d,
J58.8 Hz, H-3b, 5b), 6.85 (2H, d, J58.8 Hz, H-2b, 6b), 6.89 (1H, br s, H14a)*, 7.25 (2H, d, J58.8 Hz, H-3b, 5a), 7.67 (2H, d, J58.8 Hz, H-2a, 6a)
(* interchangeable).
Compound 4 (Hemsleyanol B) A yellow amorphous solid. Negative ion HR-FAB-MS: ([M2H]2) m/z 695.1907 (Calcd for C42H31O10:
695.1916); Negative ion FAB-MS: m/z 695 ([M2H]2). UV l max (MeOH)
1
13
nm: 230, 284, 301. [a ] 24
C-NMR
D 2205 (c50.1, MeOH). The H- and
spectral data are shown in Tables 1 and 2.
Compound 5 (Resveratrol-12-C-b -glucopyranoside) A white amorphous powder. Negative ion HR-FAB-MS: ([M2H]2) m/z 389.1229 (Calcd
for C20H21O8: 389.1236); Negative ion FAB-MS: m/z 389 ([M2H]2). UV
1
l max (MeOH) nm: 217, 309, 321. [a ] 24
D 161 (c50.1, MeOH). The H- and
13
C-NMR spectral data are listed in Tables 1 and 2.
References
1) Jang M., Cai L., Udeani G. O., Slowing K. V., Thomas C. F., Beecher
C. W. W., Fong H. H. S., Farnsworth N. R., Kinghorn A. D., Mehta R.
G., Moon R. C., Pezzuto J. M., Science, 275, 218220 (1997).
2) Kitanaka S., Ikezawa T., Yasukawa K., Yamanouchi S., Takido M,.
Sung H., Kim I., Chem. Pharm. Bull., 38, 432435 (1990).
3) Inamori Y., Ogawa M., Tsujibo H., Baba K., Kozawa M., Nakamura
H., Chem. Pharm. Bull., 39, 805807 (1991).
4) Murakami S., Arai I., Muramatsu M., Otomo S., Baba K., Kido T.,
Kozawa M., Biochem. Pharm., 44, 3337 (1992).
5) Gorham J., The Biochemistry of the Stilbenoids, Chapman & Hall,
London, 1995.
6) Sotheeswaran S., Pasupathy V., Phytochemistry, 32, 10831092
(1993).
7) Oshima Y., Ueno U., Hikino H., Tetrahedron, 46, 51215126 (1990).
8) Champika D. M. N., Sotheeswaran S., Surendrakumar S., Balasubramanian, S., Bokel M., Kraus W., J. Chem. Soc. Perkin Trans. I, 1985,
18071809.
9) El-Sohly H. N., Joshi A., Li X.-C., Ros S. A., Phytochemistry, 52,
141145 (1999).
10) Tanaka T., Ito T., Ichise M., Iinuma M., Ohyama M., Tateishi Y., Phytochemistry, accepted.
11) Coggon P., Janes N. F., King F. E., Molyneux R. J., Morgan J. W. W.,
Sellars K., J. Chem. Soc., 1965, 406508.
12) Ito J., Niwa M., Oshima Y., Heterocycles, 45, 18091813 (1997).